Prevalence of transmitted drug resistance mutations in HIV-1-infected drug-naive patients from Urban and Suburban Regions of Kenya

Simon Onsongo, Syed Hani Abidi, Samoel Khamadi, Reena Shah, Sheila Kageha, Peter Ojwang, Syed Ali, Nancy Okinda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

HIV was first described in Kenya in 1984-1985. Currently, Kenya has an estimated HIV-1 prevalence of 6.2%. With the introduction of antiretroviral drugs, the survival of most HIV patients has been prolonged markedly. However, this is greatly threatened by increasing rates of antiretroviral dug resistance, which may eventually lead to suboptimal treatment outcomes. The objective of this study was to characterize currently occurring antiretroviral drug resistance mutations among drug-naive patients visiting two referral hospitals in Kenya. Using polymerase chain reaction, the HIV protease gene was amplified from blood samples of 63 study participants. The sequences were used to determine HIV-1 subtype and presence/prevalence of mutations associated with resistance to protease inhibitors. Finally, the protease gene was variably measured using Shannon entropy analysis. Analysis of frequency of HIV-1 subtypes revealed subtype A to be the predominant subtype, while the analysis of drug resistance mutations revealed the presence of four minor drug resistance mutations associated weakly with resistance to protease inhibitors. Among these mutations, L33I was the most prevalent mutation. Shannon entropy analysis revealed high genomic variability, especially in region spanning nucleotides 1-55, 113-170, and 205-240. This study warrants the need for dedicated efforts to improve compliance to antiretroviral therapy and reduce transmitted resistance rates, which will greatly ensure the therapeutic efficacy of antiretroviral drugs.

Original languageEnglish
Pages (from-to)220-225
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume32
Issue number3
DOIs
Publication statusPublished - Mar 1 2016
Externally publishedYes

Fingerprint

Kenya
Drug Resistance
HIV-1
Mutation
Pharmaceutical Preparations
Entropy
Protease Inhibitors
HIV
HIV Protease
Genes
Compliance
Peptide Hydrolases
Referral and Consultation
Nucleotides
Polymerase Chain Reaction
Survival
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Prevalence of transmitted drug resistance mutations in HIV-1-infected drug-naive patients from Urban and Suburban Regions of Kenya. / Onsongo, Simon; Abidi, Syed Hani; Khamadi, Samoel; Shah, Reena; Kageha, Sheila; Ojwang, Peter; Ali, Syed; Okinda, Nancy.

In: AIDS Research and Human Retroviruses, Vol. 32, No. 3, 01.03.2016, p. 220-225.

Research output: Contribution to journalArticle

Onsongo, Simon ; Abidi, Syed Hani ; Khamadi, Samoel ; Shah, Reena ; Kageha, Sheila ; Ojwang, Peter ; Ali, Syed ; Okinda, Nancy. / Prevalence of transmitted drug resistance mutations in HIV-1-infected drug-naive patients from Urban and Suburban Regions of Kenya. In: AIDS Research and Human Retroviruses. 2016 ; Vol. 32, No. 3. pp. 220-225.
@article{5c51aa29afed4a9ca5b45afc6e89d447,
title = "Prevalence of transmitted drug resistance mutations in HIV-1-infected drug-naive patients from Urban and Suburban Regions of Kenya",
abstract = "HIV was first described in Kenya in 1984-1985. Currently, Kenya has an estimated HIV-1 prevalence of 6.2{\%}. With the introduction of antiretroviral drugs, the survival of most HIV patients has been prolonged markedly. However, this is greatly threatened by increasing rates of antiretroviral dug resistance, which may eventually lead to suboptimal treatment outcomes. The objective of this study was to characterize currently occurring antiretroviral drug resistance mutations among drug-naive patients visiting two referral hospitals in Kenya. Using polymerase chain reaction, the HIV protease gene was amplified from blood samples of 63 study participants. The sequences were used to determine HIV-1 subtype and presence/prevalence of mutations associated with resistance to protease inhibitors. Finally, the protease gene was variably measured using Shannon entropy analysis. Analysis of frequency of HIV-1 subtypes revealed subtype A to be the predominant subtype, while the analysis of drug resistance mutations revealed the presence of four minor drug resistance mutations associated weakly with resistance to protease inhibitors. Among these mutations, L33I was the most prevalent mutation. Shannon entropy analysis revealed high genomic variability, especially in region spanning nucleotides 1-55, 113-170, and 205-240. This study warrants the need for dedicated efforts to improve compliance to antiretroviral therapy and reduce transmitted resistance rates, which will greatly ensure the therapeutic efficacy of antiretroviral drugs.",
author = "Simon Onsongo and Abidi, {Syed Hani} and Samoel Khamadi and Reena Shah and Sheila Kageha and Peter Ojwang and Syed Ali and Nancy Okinda",
year = "2016",
month = "3",
day = "1",
doi = "10.1089/aid.2015.0026",
language = "English",
volume = "32",
pages = "220--225",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Prevalence of transmitted drug resistance mutations in HIV-1-infected drug-naive patients from Urban and Suburban Regions of Kenya

AU - Onsongo, Simon

AU - Abidi, Syed Hani

AU - Khamadi, Samoel

AU - Shah, Reena

AU - Kageha, Sheila

AU - Ojwang, Peter

AU - Ali, Syed

AU - Okinda, Nancy

PY - 2016/3/1

Y1 - 2016/3/1

N2 - HIV was first described in Kenya in 1984-1985. Currently, Kenya has an estimated HIV-1 prevalence of 6.2%. With the introduction of antiretroviral drugs, the survival of most HIV patients has been prolonged markedly. However, this is greatly threatened by increasing rates of antiretroviral dug resistance, which may eventually lead to suboptimal treatment outcomes. The objective of this study was to characterize currently occurring antiretroviral drug resistance mutations among drug-naive patients visiting two referral hospitals in Kenya. Using polymerase chain reaction, the HIV protease gene was amplified from blood samples of 63 study participants. The sequences were used to determine HIV-1 subtype and presence/prevalence of mutations associated with resistance to protease inhibitors. Finally, the protease gene was variably measured using Shannon entropy analysis. Analysis of frequency of HIV-1 subtypes revealed subtype A to be the predominant subtype, while the analysis of drug resistance mutations revealed the presence of four minor drug resistance mutations associated weakly with resistance to protease inhibitors. Among these mutations, L33I was the most prevalent mutation. Shannon entropy analysis revealed high genomic variability, especially in region spanning nucleotides 1-55, 113-170, and 205-240. This study warrants the need for dedicated efforts to improve compliance to antiretroviral therapy and reduce transmitted resistance rates, which will greatly ensure the therapeutic efficacy of antiretroviral drugs.

AB - HIV was first described in Kenya in 1984-1985. Currently, Kenya has an estimated HIV-1 prevalence of 6.2%. With the introduction of antiretroviral drugs, the survival of most HIV patients has been prolonged markedly. However, this is greatly threatened by increasing rates of antiretroviral dug resistance, which may eventually lead to suboptimal treatment outcomes. The objective of this study was to characterize currently occurring antiretroviral drug resistance mutations among drug-naive patients visiting two referral hospitals in Kenya. Using polymerase chain reaction, the HIV protease gene was amplified from blood samples of 63 study participants. The sequences were used to determine HIV-1 subtype and presence/prevalence of mutations associated with resistance to protease inhibitors. Finally, the protease gene was variably measured using Shannon entropy analysis. Analysis of frequency of HIV-1 subtypes revealed subtype A to be the predominant subtype, while the analysis of drug resistance mutations revealed the presence of four minor drug resistance mutations associated weakly with resistance to protease inhibitors. Among these mutations, L33I was the most prevalent mutation. Shannon entropy analysis revealed high genomic variability, especially in region spanning nucleotides 1-55, 113-170, and 205-240. This study warrants the need for dedicated efforts to improve compliance to antiretroviral therapy and reduce transmitted resistance rates, which will greatly ensure the therapeutic efficacy of antiretroviral drugs.

UR - http://www.scopus.com/inward/record.url?scp=84960116070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960116070&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0026

DO - 10.1089/aid.2015.0026

M3 - Article

VL - 32

SP - 220

EP - 225

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 3

ER -